Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Antibe Therapeutics Inc. ATBPF OTC

Other OTC • Healthcare • Medical - Devices • CA • USD

SharesGrow Score
29/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Antibe Therapeutics Inc. (ATBPF) is a Medical - Devices company in the Healthcare sector, currently trading at $0.22. It has a SharesGrow Score of 26/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net income is $19M (loss), growing at -3%/yr. Net profit margin is 0% (thin). Gross margin is 36.5% (-1.7 pp trend).

Balance sheet: total debt is $0 against $40M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 15.03 (strong liquidity). Debt-to-assets is 0%. Total assets: $71M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 32/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

ATBPF SharesGrow Score Overview

38/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 32/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATBPF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
ATBPF: -49.8%/yr revenue is, -3%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ATBPF: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 15.03 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
32/100
ATBPF: Gross margin is 36.5% (-1.7 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 32/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.1889-0.216
Volume17.94K
Avg Volume (30D)9.61K
Market Cap$11.43M
Beta (1Y)0.58
Share Statistics
EPS (TTM)-0.37
Shares Outstanding$52.29M
IPO Date2014-10-09
Employees11
CEODaniel Marcel Legault
Financial Highlights & Ratios
EBITDA$-19.19M
Net Income$-19.48M
Operating Income$-20.55M
Total Cash$38.89M
Net Debt$-6.76M
Total Assets$70.56M
Price / Earnings (P/E)-0.6
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA0370255097

Price Chart

Track all markets on TradingView
ATBPF
Antibe Therapeutics Inc. ↗  ·  Other OTC
Healthcare • Medical - Devices
0.19 52WK RANGE 0.22

People Also View

CMVLF
CMVLF
Cellectis S.A.
$3.08
-30.00%
 CVALF
CVALF
Covalon Technologies Ltd.
$1.44
-0.69%
 BITRF
BITRF
Biotron Limited
$0.03
+0.00%
 CRPOF
CRPOF
Ceapro Inc.
$0.17
-13.04%
 CPMV
CPMV
Mosaic ImmunoEngineering Inc.
$0.70
+0.00%
 BCDAW
BCDAW
BioCardia, Inc.
$0.01
-3.17%
 BIOAF
BIOAF
Bioasis Technologies Inc.
$0.00
+0.00%
 AVXT
AVXT
AVAX Technologies, Inc.
$0.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message